ARTICLE | Clinical News

Sensamide formulation of metoclopramide data

November 15, 1993 8:00 AM UTC

Interim analysis of a trial in 25 patients with fatal, inoperable cancers showed that the 14 who got radiation combined with the agent had an average survival time of 395 days, almost double that of the 11 patients treated with radiation alone. The investigator-initiated, Swedish trial was not randomized. ...